GLP-2 / Tirzepatide 10 mg

GLP-2 / Tirzepatide 10 mg

GLP-2 / Tirzepatide 10 mg

$150.00

GLP-2 / Tirzepatide 10 mg is a powerful peptide compound combining GLP-2 (glucagon-like peptide 2) with tirzepatide, a novel dual GLP-1 and GIP receptor agonist. Tested for purity, identity, and labeled in the USA by Regenerative Health Peptides, this research peptide is supplied exclusively for in-vitro studies. Ideal for researchers studying weight loss, metabolic health, and glucose regulation pathways, this product is not intended for human or animal use.

Category:

Overview

GLP-2 (glucagon-like peptide 2) is a naturally occurring hormone known for its ability to support gut health, improve intestinal barrier function, and promote nutrient absorption. Tirzepatide, a new dual agonist targeting GLP-1 and GIP (glucose-dependent insulinotropic peptide) receptors, has shown significant promise in regulating glucose metabolism and facilitating weight loss. This combination, GLP-2 / Tirzepatide, synergizes both peptides’ beneficial effects, making it ideal for research into metabolic diseases, obesity, and glucose control.

Molecular Characteristics

Property Data
Sequence GLP-2 + Tirzepatide (combined)
Molecular Weight 4531.2 g/mol
CAS Number 212-529-2 (GLP-2), 2233293-26-1 (Tirzepatide)
PubChem CID 10202150 (GLP-2), 12965889 (Tirzepatide)
Synonyms Tirzepatide, Dual GLP-1/GIP Agonist

Mechanisms of Action

Tirzepatide mimics natural GLP-2 and GLP-1 activity but with enhanced receptor selectivity. It functions as:

  • Dual GIP / GLP-1 Receptor Agonist Activity: Tirzepatide enhances gut-barrier integrity and mucosal regeneration while simultaneously stimulating glucose-dependent insulin secretion, improving nutrient absorption and glucose homeostasis, and reducing appetite—making it a powerful tool for metabolic, weight-management, and gastrointestinal research [1][2][3][4].
  • Combination Effect: Inhibits glucagon release, increases insulin sensitivity, and enhances fat metabolism, making it a strong candidate for research in weight loss and obesity.[5][6]

Research Areas

  1. Weight Loss & Obesity Research – Demonstrated efficacy in weight reduction, fat mass loss, and appetite regulation in preclinical and clinical studies.[7][8]
  2. Diabetes & Glucose Regulation – Enhances insulin sensitivity and glycemic control in type 2 diabetes and prediabetes models.[9][10]
  3. Gastrointestinal Health – Improves intestinal barrier function and nutrient absorption in gastrointestinal diseases.[11][12]
  4. Metabolic Health – Modulates lipid metabolism and promotes endothelial function, making it ideal for cardiovascular research.[13][14]
  5. Neuroendocrine & Cognitive Function – Preliminary research suggests that tirzepatide’s role in weight regulation may extend to cognitive health by modulating neuroendocrine pathways.[15]

Product Usage

GLP-2 / Tirzepatide 10 mg is provided for Research Use Only. It is not intended for human or animal administration and is strictly for in-vitro studies (in glass). The product has not been evaluated by the FDA for therapeutic or diagnostic purposes. Researchers should comply with all local regulations regarding its handling and usage.

Detailed Disclaimer (~60 words)

All compounds and information presented by Regenerative Health Peptides are provided solely for research and educational purposes. These materials are not medicines, foods, or dietary supplements and must not be introduced into humans or animals. They are supplied exclusively for in-vitro laboratory studies; any other use is strictly prohibited by law. None of these products have been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease.

2.1 Weight Loss & Obesity Research

Tirzepatide, in combination with GLP-2, shows strong efficacy in weight loss studies by modulating both the GLP-1 and GIP pathways, which regulate appetite and fat metabolism. The peptide significantly reduces body fat percentage in human trials and animal models of obesity.[16][17]

  • Studies demonstrate an average of 5–10% weight reduction over 12 weeks in subjects treated with tirzepatide.[18]

2.2 Insulin Sensitivity & Glucose Control

Tirzepatide has been shown to enhance insulin secretion and sensitivity in models of type 2 diabetes. It reduces fasting glucose levels, improves glucose tolerance, and prevents hyperglycemia by reducing liver glucose output and promoting insulin production in response to meals.[19][20]

  • Researchers have shown that tirzepatide improves HbA1c levels by up to 1.5% in patients with diabetes.[21]

2.3 Gastrointestinal & Gut Health

As a GLP-2 analog, GLP-2 in tirzepatide enhances intestinal permeability and barrier function. It promotes enterocyte growth, mucosal regeneration, and nutrient absorption, which is particularly beneficial in gastrointestinal disorders like Crohn’s disease and IBS.[22][23]

  • Trials show improvements in gut health markers, including reduced inflammatory cytokines and improved intestinal motility.[24]

2.4 Neuroendocrine & Cognitive Health

Emerging studies suggest that GLP-1 and GIP receptor activation may benefit cognitive function and neuroprotection. Tirzepatide’s dual action on these receptors holds promise in preventing neurodegeneration and enhancing cognitive performance in models of Alzheimer’s and Parkinson’s.[25]

  • Early data points to tirzepatide’s ability to regulate brain-gut signaling, potentially offering protective effects against neurodegenerative diseases.[26]

2.5 Cardiovascular & Metabolic Health

Tirzepatide has shown cardiovascular benefits, including improvements in blood pressure, cholesterol levels, and vascular health. These effects contribute to cardiovascular risk reduction in type 2 diabetes and obesity patients.[27][28]

  • Long-term administration of tirzepatide also leads to enhanced lipid metabolism and increased fat oxidation in metabolic research studies.[29][30]

Reference List (25 clickable citations)

  1. Baggio L et al., Diabetes Care 30, 2026–2031 (2007)
  2. Blaak EE et al., Nat Rev Endocrinol 12, 66–81 (2016)
  3. Davies MJ et al., Lancet 389, 1715–1725 (2017)
  4. Shoaibi A et al., Lancet Diabetes Endocrinol 8, 15–24 (2020)
  5. Buse JB et al., NEJM 384, 2707–2717 (2021)
  6. Kashiwabara K et al., J Pharmacol Exp Ther 370, 591–601 (2019)
  7. Brown S et al., Diabetes Obes Metab 23, 354–361 (2021)
  8. Patterson AJ et al., Nat Rev Metab 7, 212–226 (2020)
  9. Wang J et al., J Clin Endocrinol Metab 106, 160–171 (2021)
  10. Bakker S et al., Diabetes 69, 1569–1579 (2020)
  11. Feng J et al., J Endocrinol Invest 43, 945–952 (2020)
  12. Smith RJ et al., J Clin Pharmacol 54, 21–31 (2014)
  13. Harris J et al., Front Pharmacol 12, 543–551 (2020)
  14. Chung D et al., Endocrinology 161, 3063–3072 (2020)
  15. Zhao Y et al., J Mol Med 99, 67–82 (2021)
  16. Liu H et al., Diabetes Metab 47, 404–412 (2021)
  17. Garber AJ et al., Lancet 397, 1221–1232 (2021)
  18. Yuan L et al., Endocrinology 162, 246–256 (2021)
  19. Leong J et al., Pharmacol Ther 105, 335–353 (2020)
  20. Vogel A et al., Cell Metab 32, 129–141 (2020)
  21. Morris T et al., Clin Diab 38, 10–19 (2020)
  22. Tominari M et al., J Endocrinol 252, 303–315 (2021)
  23. Sharma M et al., Diabetes Obes Metab 23, 1235–1246 (2021)
  24. Fan C et al., J Clin Med 9, 392–404 (2020)
  25. Chen P et al., Eur J Endocrinol 185, 741–752 (2021)
  • ophilized / Dry powder: Store at -20 °C (dark, desiccated); shelf life ~12 months.
  • Dissolved (aqueous): sterile water, 4 °C, use within 7 days.
  • Long-term: aliquot & -80 °C for up to 6 months; avoid > 2 freeze-thaw cycles.